Biodistribution of Adeno-Associated Virus Gene Therapy Following Cerebrospinal Fluid-Directed Administration
Authors:
- 1 February 2023
- journal article
- research article
- Published by SAGE Publications in Human Gene Therapy
- Vol. 34 (3-4) , 94-111
Abstract
Adeno-associated virus (AAV)-based gene therapies, exemplified by the approved therapy for spinal muscular atrophy, have the potential to deliver disease-course–altering treatments for central nervous system (CNS) indications. However, several clinical trials have reported severe adverse events including patient deaths following high-dose systemic administration for muscle-directed gene transfer, highlighting the need to explore approaches utilizing lower doses when targeting the CNS. Animal models of disease provide insight into the response to new AAV therapies. However, translation from small to larger animals and eventually to humans is hampered by anatomical and biological differences across the species and their impact on AAV delivery. We performed a literature review of preclinical studies of AAV gene therapy biodistribution following cerebrospinal fluid (CSF) delivery (intracerebroventricular, intra-cisterna magna, and intrathecal lumbar). The reviewed literature varies greatly in the reported biodistribution of AAV following administration into the CSF. Differences between studies including animal model, vector serotype used, method used to assess biodistribution, and route of administration, among other variables, contribute to differing outcomes and difficulties in translating these preclinical results. For example, only half of the published AAV-based gene therapy studies report vector copy number, the most direct readout following administration of a vector; none of these studies reported details such as the empty:full capsid ratio and quality of encapsidated genome. Analysis of the last decade’s literature focusing on AAV-based gene therapies targeting the CNS underscores limitations of the body of knowledge and room for continued research. In particular, there is a need to understand the biodistribution achieved by different CSF-directed routes of administration and determining if specific cell types/structures of interest will be transduced. Our findings point to a clear need for a more systematic approach across the field to align the assessments and elements reported in preclinical research to enable more reliable translation across animal models and into human studies.Keywords
This publication has 87 references indexed in Scilit:
- Capsid Serotype and Timing of Injection Determines AAV Transduction in the Neonatal Mice BrainPLOS ONE, 2013
- Adeno-Associated Virus Serotype 9 Transduction in the Central Nervous System of Nonhuman PrimatesHuman Gene Therapy, 2012
- Neutralizing Antibodies Against AAV Serotypes 1, 2, 6, and 9 in Sera of Commonly Used Animal ModelsMolecular Therapy, 2012
- Preclinical Differences of Intravascular AAV9 Delivery to Neurons and Glia: A Comparative Study of Adult Mice and Nonhuman PrimatesMolecular Therapy, 2011
- AAV-mediated photoreceptor transduction of the pig cone-enriched retinaGene Therapy, 2011
- Drug transport in brain via the cerebrospinal fluidFluids and Barriers of the CNS, 2011
- Characterization of a Recombinant Adeno-Associated Virus Type 2 Reference Standard MaterialHuman Gene Therapy, 2010
- Comparison of AAV Serotypes for Gene Delivery to Dorsal Root Ganglion NeuronsMolecular Therapy, 2010
- Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytesNature Biotechnology, 2008
- Neonatal Intraperitoneal or Intravenous Injections of Recombinant Adeno-Associated Virus Type 8 Transduce Dorsal Root Ganglia and Lower Motor NeuronsHuman Gene Therapy, 2008